C/EBPβ enhances efficacy of sorafenib in hepatoblastoma
| Autor: | Hao Miao, Nana Guo, Baoqun Li, Chong Pang, Dayong Sun, Yanzhen Zuo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Sorafenib Hepatoblastoma Male Normal tissue Mice Nude Antineoplastic Agents 03 medical and health sciences Mice 0302 clinical medicine Migration inhibition Medicine Animals Humans Child Messenger RNA business.industry CCAAT-Enhancer-Binding Protein-beta Liver Neoplasms Cell Biology General Medicine Hep G2 Cells medicine.disease Tumor tissue digestive system diseases Clinical trial 030104 developmental biology Cell culture 030220 oncology & carcinogenesis Cancer research Female business medicine.drug |
| Zdroj: | Cell biology internationalREFERENCES. 45(9) |
| ISSN: | 1095-8355 |
| Popis: | Hepatoblastoma (HB) is the predominant hepatic neoplasm in infants and young children. Sorafenib has been used to treat adult and pediatric hepatocellular carcinoma. However, efficacy of monotherapy of sorafenib in HB is not sustained. In this study, we tested a possible combinatory therapy of sorafenib with the CCAAT/enhancer-binding proteins (C/EBP) overexpression in HB cell line. Firstly, we evaluated the expression level of C/EBPβ in the patients with HB by analyzing The Cancer Genome Atlas data. Lower level of C/EBPβ was observed in tumor tissues in comparison with matched normal tissues. Next, we observed that combination of sorafenib and C/EBPβ overexpression led to dramatic growth and migration inhibition of live tumor cells which implied promising probability for clinical trial. Mechanistically, C/EBPβ which can be downregulated by Ras v12, augmented messenger RNA and protein levels of p53. These data suggested that a combination of sorafenib and C/EBPβ overexpression inhibited tumor growth synergistically and provided a promising approach to treat HB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text